Genmab A (GMAB) Net Cash Flow (2018 - 2026)

Genmab A has reported Net Cash Flow for 7 years, with the latest figure at -$183.0 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 179.22% year-over-year to -$183.0 million; the trailing twelve-month figure through Mar 2026 stood at $191.0 million (up 106.22% YoY), and the FY2025 full-year result was $332.0 million, up 137.43% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$183.0 million, down from $461.0 million in the prior quarter.
• The five-year high for Net Cash Flow was $461.0 million in Q3 2025, with the low at -$4.9 billion in Q4 2023.
• Historically, Net Cash Flow has averaged -$874.0 million across 4 years, with a median of -$87.0 million in 2025.
• Annual changes were most pronounced in 2025 — Net Cash Flow jumped 403.95% — and 2026, when it plunged 179.22%.
• Genmab A's Net Cash Flow stood at -$4.9 billion in 2023, then surged by 59.01% to -$2.0 billion in 2024, then surged by 122.9% to $461.0 million in 2025, then tumbled by 139.7% to -$183.0 million in 2026.
• The last three Net Cash Flow figures came in at -$183.0 million (Q1 2026), $461.0 million (Q3 2025), and -$87.0 million (Q2 2025), per Business Quant data.